Pulmonary Arterial Hypertension Studies, NIH Grant #1 RO1 HL078946-01 (Collaborator), 7/1/05 – 6/30/09
Pharmacogenomics in Pulmonary Arterial Hypertension. The major goal of this study is to determine clinically in PAH parients if associations exist between the efficacy and toxicity of bosentan, the most widely used therapy for PAH, and sitaxsentan, a new agent with the only ongoing large clinical trials with several gene polymorphisms in several key disease-specific and therapy-specific genes. Role: PI
Actelion Clinical Operations AC0052-364, 12/1/05 – 11/29/08
EARLY: Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients with Mildly Symptomatic Pulmoanry Arterial Hypertension. The major goal of this study is to demonstrate that bosentan improves cardiac hemodynamics and, as subordinate, exercise capacity in mildly symptomatic PAH patients. Role: PI
MD Primer, Inc. (Actelion, Inc.)/MOU, 3/21/06
PAH-QuERI Registry: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative. The major goal of this initiative is to facilitate access to published PAH guidelines by participating physicians and to allow them an opportunity of evaluating the applicability of the guidelines to their practice and ability to adhere to the guidelines as part of their patient management. Role: PI
Co-Therix, Inx. C200-006, Pending
VISION: Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients with Pulmonary Arterial Hypertension receiving Oral Sildenafil..The primary goaal of this study is to assess the efficacy of the addition of inhaled iloprost vs. placebo in patients with PAH receiving sildenafil. Role: PI
Actelion, Inc. AC-052-414, Pending
COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients with Pulmonary Arterial Hypertension. The major goal is to demonstrate that the combination of bosentan and sildenafil prolongs the time to the first adjudicated morbidity/mortality event compared with sildenafil monotherapy in symptomatic patients with PAH. Role: PI
Co-Therix, Inc., Pending
REVEAL: Registry to Evaluate Early and Long-Term PAH Disease Management. The major goal is to characterize the demographics and clinical course of the patient population diagnosed with WHO Group I PAH. Role: PI
Park MH, Uber PA. Primary Pulmonary Hypertension: A Daunting Clinical Entity. The Ochsner Journal 2000;2,Suppl.1:s39-45.
Park MH, Starling R. Does Aspirin Interact with ACE Inhibitors in Patients with Heart Failure? The Ochsner Journal 2000 July;2,Suppl.1:s23-28.
Mehra MR, Uber PA, Prasad AK, Park MH, Scott RL, McFadden PM, Van Meter CH. Long-Term Outcome of Cardiac Allograft Vasculopathy Treated by Transmyocardial Laser Revascularization: Early Rewards, Late Losses. J Heart Lung Transplant 2000 Aug;19(8):801-804.
Uber PA, Mehra MR, Scott RL, Prasad AK, Park MH. Ethnic Disparities in the Pharmacological Characteristics of Tacrolimus in Heart Transplantation. Transplant Proc 2001 Feb-Mar;33(1-2):1581-2.
Mehra MR, Uber PA, Scott RL, Srigiri K, Pulakurthi S, Prasad AK, Dumas-Hicks D, Park MH. Racial Differences in Clinical Outcome Using Tacrolimus and Mycophenolate Mofetil Immunosuppression in Heart Transplantation. Transplant Proc 2001 Feb-Mar;33(1-2):1613-1614.
Mehra MR, Uber PA, Park MH, Prasad AK, Scott RL. A Randomized Comparison of an Immunosuppressive Strategy Using Tacrolimus and Cyclosporine in Black Heart Transplant Recipients. Transplant Proc 2001 Feb-Mar;33(1-2):1606-7.
Park MH, Scott RL, Uber PA, Mehra MR. Bedside B-type Natriuretic Peptide and Acute Non-Cellular Cardiac Allograft Rejection. J Heart & Lung Transplant 2002 May;21(5):613-4.
Park MH. Timely Intervention in Asymptomatic Aortic Stenosis: Emerging Clinical Parameters May Help Predict Outcomes. Postgraduate Medicine 2001;110(2):28-40.
Grant AIII, Uber PA, Park MH, Scott RL, Mehra MR. Difficult Cases in Heart Failure. Novel Diagnostic Markers in Heart Failure: An Emerging Paradigm Shift? Congest Heart Fail 2001 Sep-Oct;7(5):274-276.
Beckman EN, Mehra MR, Park MH, Scott RL. Utility of Heart Biopsy in Transplant Patients. The Ochsner Journal 2001 Oct;3(4):219-222.
Grant AC, Uber PA, Park MH, Scott RL, Mehra MR. Novel Diagnostic Markers in Heart Failure: An Emerging Paradigm Shift? Congest Heart Fail 2001;7:274-276.
Mehra MR, Uber PA, Uber WE, Park MH, Scott RL. Anything but a Biopsy: Non-Invasive Monitoring for Cardiac Allograft Rejection. Curr Opin Cardiol 2002 Mar;17(2):131-136.
Sangha SS, Uber PA, Park MH, Scott RL, Mehra MR. Difficult Cases in Heart Failure: The Challenge of Neurocognitive Dysfunction in Severe Heart Failure. Congest Heart Fail 2002 Jul-Aug;8(4):232-4.
Uber PA, Mehra MR, Harris B, Scott RL, Park MH. Steroid Weaning in Heart Transplantation is Associated with Decreased B-Type Natriuretic Peptide: Surrogate Evidence for Cardiac Adaptation. Transplant Proc 2002 Aug;34(5):1843.
Mehra MR, Uber PA, Scott RL, Park MH, Milani RV. The Effect of Immunosuppressive Regimen on Novel Markers of Atherothrombosis in Heart Transplantation: Homocysteine, C-Reactive Protein, and Mean Platelet Volume. Transplant Proc 2002 Aug;34(5):1866.
Vivekananthan K, Kalapura T, Mehra MR, Lavie CJ, Milani RV, Scott RL, Park MH. Usefulness of the Combined Index of Systolic and Diastolic Myocardial Performance to Identify Cardiac Allograft Rejection. Am J Card 2002 Sep 1;90(5):517.
Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, Milani RV, Lavie CJ. Comparative Beneficial Effects of Simvastatin and Pravastatin on Cardiac Allograft Rejection and Survival. J Am Coll Card 2002 Nov 6;40(9):1609-14.
Park MH, Scott RL, Uber PA, Mehra MR. Treatment of Pulmonary Hypertension: A Promising New Age. Catheter Cardiovasc Interv 2002 Nov;57(3):395-403.
Park MH, Scott RL, Uber PA, Harris BC, Chambers R, Mehra MR. Usefulness of B-type Natriuretic Peptide Levels in Predicting Hemodynamic Perturbations After Heart Transplantation Despite Preserved Left Ventricular Systolic Function. Am J Card 2002 Dec 15;90(12):1326-1329.
Mehra MR, Uber PA, Park MH, Scott RL. Ethnic Disparity in Clinical Outcome After Heart Transplantation is Abrogated Using Tacrolimus and Mycophenolate Mofetil Based Immunosuppression. Transplantation 2002 Dec 15;74(11):1568-73.
Uber PA, Mehra MR, Park MH, Scott RL. Clopidogrel and Rhabdomyolysis Following Heart Transplantation. J Heart & Lung Transplant 2003;22:107-108.
Mehra MR, Ventura HO, Uber PA, Scott RL, Park MH. Is All Intimal Proliferation Created Equal in Cardiac Allograft Vasculopathy? The Quantity-Quality Paradox. J Heart & Lung Transplant 2003 Feb;22(2):118-123.
Mehra MR, Uber PA, Uber WE, Scott RL, Park MH. Allosensitization in Heart Transplantation: Implications and Management Strategies. Curr Opin Cardiol 2003;18(2):153-158.
Alaeddini J, Uber P, Park MH, Scott RL, Mehra MR. Difficult Cases in Heart Failure: Sildenafil and Assessment of Pulmonary Arterial Reactivity in Heart Failure. Congest Heart Fail 2003 May/June;9:176-178.
Park MH. Should Aspirin be used with Angiotensin-Converting Enzyme Inhibitors in Patients with Chronic Heart Failure? Congest Heart Fail 2003 July/August;9:206-213.
Park MH, Uber PA, Scott RL, Mehra MR. B-Type Natriuretic Peptide in Heart Transplantation: An Important Marker of Allograft Performance. Heart Fail Rev 2003 Oct;8(4):359-63.
Mehra MR, Uber PA, Ventura, HO, Scott RL, Park MH. The Impact of Mode of Donor Brain Death on Cardiac Allograft Vasculopathy: An Intravascular Ultrasound Study. J Am Coll Cardiol 2004;43:806-810.
Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and Suppressed B-Type Natriuretic Peptide Levels in Heart Failure. J Am Coll Cardiol 2004 May 5;43(9):1590-1595.
Mehra MR, Uber PA, Potluri S, Ventura HO, Scott RL, Park MH. Usefulness of an Elevated B-Type Natriuretic Peptide Allograft Failure, Cardiac Allograft Vasculopathy and Survival after Heart Transplantation. Am J Cardiol 2004;94(4):454-458.
Potluri S, Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO. The Relationship between Epicardial Coronary Disease, Tissue Myocardial Perfusion and Survival in Heart Transplantation. J Heart Lung Transplant 2004. In press.
Park MH, Scott RL, Uber PA, Ventura HO, Mehra MR. Usefulness of B-Type Natriuretic Peptide as a Predictor of Treatment Outcome in Pulmonary Arterial Hypertension. Congest Heart Fail 2004 Sep-Oct;10(5):221-5.
Alaeddini J, Uber PA, Park MH, Scott RL, Ventura HO, Mehra MR. Efficacy and Safety of Sildenafil in the Evaluation of Pulmonary Hypertension in Severe Heart Failure. Am J Cardiol 2004;94(11):1475-1477.
Mehra MR, Milani R, Richie M, Uber PA, Park MH, Ventura HO, Scott RL, Lavie CJ. Ventricular-Vascular Uncoupling Increases Expression of B-Type Natriuretic Peptide in Heart Transplantation. Transplant Proc 2004;36(10):3149-3155.
Mehra MR, Uber PA, Park MH, Ventura HO, Scott R. Corticosteroid Weaning in the Tacrolimus and Mycophenolate Era in Heart Transplantation: Clinical and Neurohormonal Benefits. Transplant Proc 2004;35(10):3152-3155.
Park MH. Commentary: Trial finds no evidence that aspirin and warfarin improve outcomes in people with heart failure. Evidence-Based Cardiovascular Medicine 2004;8(4):313-314.
Potluri S, Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO. The relationship between epicardial coronary disease, tissue myocardial perfusion and survival in heart transplantation. J Heart Lung Transplant 2005;24:1019-25.
Mehra MR, Uber PA, Prasad A, Scott RL, Park MH. Recrudescent tobacco exposure following heart transplantation: clinical profiles and relationships with athero-thrombosis risk markers. Amer J of Transplantation 005;5(5):1137-1140.